Catalyst Pharmaceuticals Company Profile (NASDAQ:CPRX)

About Catalyst Pharmaceuticals (NASDAQ:CPRX)

Catalyst Pharmaceuticals logoCatalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CPRX
  • CUSIP: N/A
  • Web: www.catalystpharma.com
Capitalization:
  • Market Cap: $179.3 million
  • Outstanding Shares: 83,786,000
Average Prices:
  • 50 Day Moving Avg: $1.86
  • 200 Day Moving Avg: $1.40
  • 52 Week Range: $0.59 - $2.35
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.30
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.42 per share
  • Price / Book: 5.10
Profitability:
  • EBIDTA: ($17,080,000.00)
  • Return on Equity: -43.03%
  • Return on Assets: -40.38%
Debt:
  • Current Ratio: 22.64%
  • Quick Ratio: 22.64%
Misc:
  • Average Volume: 1.24 million shs.
  • Beta: 2.26
  • Short Ratio: 1.39
 

Frequently Asked Questions for Catalyst Pharmaceuticals (NASDAQ:CPRX)

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) issued its earnings results on Wednesday, May, 10th. The company reported ($0.06) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.06). View Catalyst Pharmaceuticals' Earnings History.

Where is Catalyst Pharmaceuticals' stock going? Where will Catalyst Pharmaceuticals' stock price be in 2017?

3 equities research analysts have issued twelve-month price objectives for Catalyst Pharmaceuticals' stock. Their forecasts range from $3.00 to $6.00. On average, they expect Catalyst Pharmaceuticals' stock price to reach $4.33 in the next twelve months. View Analyst Ratings for Catalyst Pharmaceuticals.

Are investors shorting Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals saw a decrease in short interest during the month of April. As of April 13th, there was short interest totalling 2,683,843 shares, a decrease of 3.7% from the March 31st total of 2,786,600 shares. Based on an average trading volume of 705,661 shares, the short-interest ratio is currently 3.8 days.

Who are some of Catalyst Pharmaceuticals' key competitors?

Who owns Catalyst Pharmaceuticals stock?

Catalyst Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Broadfin Capital LLC (9.88%), Vanguard Group Inc. (3.63%), Point72 Asset Management L.P. (1.06%), Candriam Luxembourg S.C.A. (0.00%), Geode Capital Management LLC (0.56%) and Renaissance Technologies LLC (0.46%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Donald A Denkhaus, M Douglas Winship, Patrick J Mcenany, Philip H Coelho and Steve Miller. View Institutional Ownership Trends for Catalyst Pharmaceuticals.

Who sold Catalyst Pharmaceuticals stock? Who is selling Catalyst Pharmaceuticals stock?

Catalyst Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P. and Kennedy Capital Management Inc.. View Insider Buying and Selling for Catalyst Pharmaceuticals.

Who bought Catalyst Pharmaceuticals stock? Who is buying Catalyst Pharmaceuticals stock?

Catalyst Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Renaissance Technologies LLC, Knott David M, JPMorgan Chase & Co., Berson & Corrado Investment Advisors LLC, Oxford Asset Management, Vanguard Group Inc. and Bank of New York Mellon Corp. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, Donald A Denkhaus, Patrick J Mcenany, Philip H Coelho and Steve Miller. View Insider Buying and Selling for Catalyst Pharmaceuticals.

How do I buy Catalyst Pharmaceuticals stock?

Shares of Catalyst Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Catalyst Pharmaceuticals stock cost?

One share of Catalyst Pharmaceuticals stock can currently be purchased for approximately $2.14.

Analyst Ratings

Consensus Ratings for Catalyst Pharmaceuticals (NASDAQ:CPRX) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.33 (102.49% upside)

Analysts' Ratings History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/20/2017Roth CapitalSet Price TargetBuy$3.00LowView Rating Details
3/20/2017HC WainwrightReiterated RatingBuy$6.00LowView Rating Details
10/5/2016Piper Jaffray CompaniesUpgradeNeutral -> Overweight$4.00N/AView Rating Details
2/20/2016SunTrust Banks, Inc.Reiterated RatingBuy$7.00 -> $6.00N/AView Rating Details
6/24/2015MLV & Co.Initiated CoverageBuy$14.00N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Earnings by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Earnings History by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.06)($0.06)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.07)($0.05)ViewN/AView Earnings Details
11/9/2016Q316($0.06)($0.05)ViewListenView Earnings Details
8/9/2016Q216($0.08)($0.06)ViewN/AView Earnings Details
5/10/2016Q116($0.07)($0.07)ViewN/AView Earnings Details
3/15/2016Q415($0.07)($0.07)ViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.06)ViewListenView Earnings Details
5/11/2015Q115($0.08)($0.06)ViewN/AView Earnings Details
3/16/2015Q414($0.07)($0.06)ViewN/AView Earnings Details
11/14/2014Q314($0.06)($0.06)ViewN/AView Earnings Details
8/14/2014Q214($0.08)($0.05)ViewN/AView Earnings Details
3/19/2014Q413($0.07)($0.02)ViewN/AView Earnings Details
11/14/2013Q3($0.07)($0.07)ViewN/AView Earnings Details
8/15/2013Q213($0.07)($0.06)ViewN/AView Earnings Details
11/15/2012Q312($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)
2017 EPS Consensus Estimate: ($0.25)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.06)($0.06)($0.06)
Q2 20171($0.06)($0.06)($0.06)
Q3 20171($0.06)($0.06)($0.06)
Q4 20171($0.07)($0.07)($0.07)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Insider Ownership Percentage: 8.79%
Institutional Ownership Percentage: 28.13%
Insider Trades by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Insider Trades by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/12/2016Charles B O'keeffeDirectorBuy20,000$0.81$16,200.00View SEC Filing  
6/17/2016Philip H CoelhoDirectorBuy15,000$0.76$11,400.00View SEC Filing  
6/14/2016Donald A DenkhausDirectorBuy50,000$0.65$32,500.00View SEC Filing  
6/14/2016Patrick J McenanyCEOBuy105,300$0.65$68,445.00View SEC Filing  
4/26/2016Charles B O'keeffeDirectorBuy20,000$0.60$12,000.00View SEC Filing  
4/26/2016Patrick J McenanyCEOBuy50,000$0.65$32,500.00View SEC Filing  
3/17/2016Philip H CoelhoDirectorBuy10,000$1.06$10,600.00View SEC Filing  
3/16/2016Charles B O'keeffeDirectorBuy10,000$1.11$11,100.00View SEC Filing  
1/11/2016Steve MillerCOOBuy7,933$1.80$14,279.40View SEC Filing  
1/8/2016Charles B O'keeffeDirectorBuy5,000$1.94$9,700.00View SEC Filing  
1/7/2016Donald A DenkhausDirectorBuy25,000$2.03$50,750.00View SEC Filing  
12/28/2015Patrick J McenanyCEOBuy25,000$2.39$59,750.00View SEC Filing  
12/23/2015Charles B O'keeffeDirectorBuy5,000$2.41$12,050.00View SEC Filing  
11/19/2015Charles B O'keeffeDirectorBuy5,000$2.30$11,500.00View SEC Filing  
10/23/2015M Douglas WinshipVPSell22,800$3.34$76,152.00View SEC Filing  
10/1/2015Patrick J McenanyCEOBuy10,000$2.81$28,100.00View SEC Filing  
5/1/2015David D MuthEVPBuy1,700$3.20$5,440.00View SEC Filing  
4/30/2015Charles B O'keeffeDirectorBuy10,000$3.29$32,900.00View SEC Filing  
4/28/2015David D MuthEVPBuy2,000$3.55$7,100.00View SEC Filing  
4/27/2015Donald A DenkhausDirectorBuy15,000$3.71$55,650.00View SEC Filing  
4/27/2015Patrick J McenanyCEOBuy5,000$3.79$18,950.00View SEC Filing  
4/24/2015Charles B O'keeffeDirectorBuy5,000$3.80$19,000.00View SEC Filing  
3/27/2015Donald A DenkhausDirectorBuy5,000$4.17$20,850.00View SEC Filing  
1/20/2015David D MuthEVPBuy21,000$2.96$62,160.00View SEC Filing  
1/13/2015Charles B O'keeffeDirectorBuy10,000$3.00$30,000.00View SEC Filing  
1/8/2015Patrick J McenanyCEOBuy50,000$2.80$140,000.00View SEC Filing  
10/3/2014David D MuthVPBuy10,000$2.65$26,500.00View SEC Filing  
6/4/2014Steve MillerCOOBuy100,000$2.17$217,000.00View SEC Filing  
5/21/2014Patrick McenanyCEOBuy25,000$1.89$47,250.00View SEC Filing  
5/19/2014Charles O'keeffeDirectorBuy10,000$1.83$18,300.00View SEC Filing  
4/16/2014Charles O'keeffeDirectorBuy5,000$2.02$10,100.00View SEC Filing  
2/7/2014Patrick McenanyCEOBuy25,000$1.82$45,500.00View SEC Filing  
2/5/2014Charles O'keeffeDirectorBuy10,000$1.81$18,100.00View SEC Filing  
10/23/2013David S TierneyDirectorBuy8,000$2.03$16,240.00View SEC Filing  
10/21/2013Charles B O'keeffeDirectorBuy10,000$1.84$18,400.00View SEC Filing  
10/21/2013Patrick J McenanyCEOBuy50,000$1.59$79,500.00View SEC Filing  
2/19/2013Patrick J McenanyCEOBuy50,000$0.46$23,000.00View SEC Filing  
12/17/2012Patrick J McenanyCEOBuy100,000$0.45$45,000.00View SEC Filing  
12/8/2012Biomarin Pharmaceutical IncMajor ShareholderBuy5,000,000$0.75$3,750,000.00View SEC Filing  
11/15/2012Patrick J McenanyCEOBuy100,000$0.42$42,000.00View SEC Filing  
11/15/2012Philip H CoelhoDirectorBuy24,000$0.41$9,840.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Latest Headlines for Catalyst Pharmaceuticals (NASDAQ:CPRX)
Source:
DateHeadline
americanbankingnews.com logoCatalyst Pharmaceuticals Inc (CPRX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 22 at 4:28 PM
globenewswire.com logoCatalyst Pharmaceuticals to Present at the Antiepileptic Drug and Device Trials XIV Symposium - GlobeNewswire (press release)
globenewswire.com - May 19 at 8:35 AM
nasdaq.com logoCatalyst Pharmaceuticals to Present at the Antiepileptic Drug and Device Trials XIV Symposium - Nasdaq
www.nasdaq.com - May 18 at 11:01 AM
finance.yahoo.com logoCatalyst Pharmaceuticals to Present at the Antiepileptic Drug and Device Trials XIV Symposium
finance.yahoo.com - May 17 at 11:29 AM
americanbankingnews.com logo-$0.06 EPS Expected for Catalyst Pharmaceuticals Inc (CPRX) This Quarter
www.americanbankingnews.com - May 12 at 8:28 PM
finance.yahoo.com logoCatalyst Pharmaceuticals Receives 2017 Beacon Council Award for Contributions in Life Sciences & Healthcare
finance.yahoo.com - May 12 at 5:00 PM
americanbankingnews.com logoCatalyst Pharmaceuticals Inc (CPRX) Issues Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - May 11 at 5:30 PM
zacks.com logoCatalyst Pharmaceuticals (CPRX) Posts Loss as Expected in Q1
www.zacks.com - May 11 at 5:04 PM
finance.yahoo.com logoInvestor Network: Catalyst Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 11 at 5:04 PM
globenewswire.com logoCatalyst Pharmaceuticals Announces Poster Presentation of MuSK ... - GlobeNewswire (press release)
globenewswire.com - May 10 at 9:48 PM
finance.yahoo.com logoCatalyst reports 1Q loss
finance.yahoo.com - May 10 at 9:48 PM
finance.yahoo.com logoCatalyst Pharmaceuticals Announces First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 10 at 4:40 PM
americanbankingnews.com logoCatalyst Pharmaceuticals Inc (CPRX) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 8 at 8:58 AM
globenewswire.com logoCatalyst Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Thursday, May 11th ... - GlobeNewswire (press release)
globenewswire.com - May 4 at 9:35 PM
nasdaq.com logoCatalyst Pharmaceuticals to Hold First Quarter Financial Results ... - Nasdaq
www.nasdaq.com - May 3 at 8:29 AM
nasdaq.com logoWhat's in Store for Catalyst (CPRX) Stock in Q1 Earnings?
www.nasdaq.com - May 2 at 7:45 PM
finance.yahoo.com logoCatalyst Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Thursday, May 11th, 2017
finance.yahoo.com - May 2 at 7:45 PM
americanbankingnews.com logoCatalyst Pharmaceuticals (CPRX) Earns Daily News Impact Score of -0.12
www.americanbankingnews.com - April 30 at 10:51 AM
americanbankingnews.com logoShort Interest in Catalyst Pharmaceuticals Inc (CPRX) Declines By 3.7%
www.americanbankingnews.com - April 29 at 11:57 PM
americanbankingnews.com logoCatalyst Pharmaceuticals (CPRX) Earns News Sentiment Score of -0.12
www.americanbankingnews.com - April 24 at 2:22 PM
americanbankingnews.com logo Brokerages Anticipate Catalyst Pharmaceuticals Inc (CPRX) to Post -$0.06 EPS
www.americanbankingnews.com - April 24 at 12:28 PM
americanbankingnews.com logoCatalyst Pharmaceuticals (CPRX) Given News Impact Score of 0.30
www.americanbankingnews.com - April 20 at 6:38 PM
nasdaq.com logoCatalyst (CPRX) Up 16.6% Since Earnings Report: Can It Continue?
www.nasdaq.com - April 19 at 12:43 PM
prnewswire.com logoResearch Reports Coverage on Generic Drugs Stocks -- Innocoll, Catalyst Pharma, Galectin Therapeutics, and ... - PR Newswire (press release)
www.prnewswire.com - April 18 at 12:17 PM
finance.yahoo.com logoCatalyst Pharmaceuticals and ZIOPHARM Oncology Bounce Up On FDA Phase News
finance.yahoo.com - March 28 at 12:29 PM
finance.yahoo.com logoCATALYST PHARMACEUTICALS, INC. Financials
finance.yahoo.com - March 24 at 4:45 PM
americanbankingnews.com logoCatalyst Pharmaceuticals Inc (CPRX) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - March 21 at 9:24 PM
americanbankingnews.com logoCatalyst Pharmaceuticals Inc (CPRX) Given a $3.00 Price Target by Roth Capital Analysts
www.americanbankingnews.com - March 21 at 3:39 PM
finance.yahoo.com logoFinancials of Aurinia Pharmaceuticals and Catalyst Pharmaceuticals are Getting Stability
finance.yahoo.com - March 21 at 11:54 AM
americanbankingnews.com logoCatalyst Pharmaceuticals Inc (CPRX) Forecasted to Post Q1 2017 Earnings of ($0.06) Per Share
www.americanbankingnews.com - March 21 at 8:50 AM
americanbankingnews.com logoCatalyst Pharmaceuticals Inc (CPRX) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - March 20 at 9:48 PM
americanbankingnews.com logoFY2020 EPS Estimates for Catalyst Pharmaceuticals Inc (CPRX) Lowered by Analyst
www.americanbankingnews.com - March 20 at 12:22 PM
seekingalpha.com logoCatalyst Pharmaceutical Partners' (CPRX) CEO Pat McEnany on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 16 at 5:49 PM
americanbankingnews.com logoCatalyst Pharmaceuticals Inc (CPRX) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - March 16 at 10:43 AM
nasdaq.com logoWhat's The Catalyst Driving CPRX?
www.nasdaq.com - March 15 at 4:52 PM
investopedia.com logoCatalyst Pharma Neuromuscular Drug Succeeds (CPRX)
www.investopedia.com - March 15 at 4:52 PM
us.rd.yahoo.com logoCatalyst Pharma Neuromuscular Drug Succeeds In Study
us.rd.yahoo.com - March 15 at 4:52 PM
us.rd.yahoo.com logoCatalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update
us.rd.yahoo.com - March 15 at 4:52 PM
marketwatch.com logoCatalyst Pharma shares jump 10% premarket on news of positive trial results for rare disease
www.marketwatch.com - March 15 at 9:44 AM
biz.yahoo.com logoQ4 2016 Catalyst Pharmaceuticals Inc Earnings Release - After Market Close
biz.yahoo.com - March 15 at 9:44 AM
finance.yahoo.com logoCatalyst Pharmaceuticals Announces Positive Data from Investigator-Sponsored Trial of Firdapse® in treating MuSK Antibody Positive Myasthenia Gravis
finance.yahoo.com - March 15 at 9:44 AM
finance.yahoo.com logo8:13 am Catalyst Pharma announces 'positive' results in a seven-patient trial evaluating Firdapse as a treatment for myasthenia gravis patients with anti-MuSK antibodies; co intends to proceed to U.S. multi-center pivotal trial
finance.yahoo.com - March 15 at 9:44 AM
finance.yahoo.com logoCatalyst Pharma's neuromuscular drug succeeds in study
finance.yahoo.com - March 15 at 9:44 AM
biz.yahoo.com logoCATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 15 at 9:44 AM
marketwatch.com logoCatalyst Pharma shares jump 22% premarket on news of positive trial results for rare disease
www.marketwatch.com - March 15 at 9:44 AM
seekingalpha.com logoCatalyst Pharmaceuticals (CPRX) Presents At 29th Annual ROTH Conference
seekingalpha.com - March 14 at 1:24 PM
finance.yahoo.com logoCatalyst Pharmaceuticals to Present at the 29th Annual ROTH Conference
finance.yahoo.com - March 10 at 11:31 AM
nasdaq.com logoCatalyst Pharmaceuticals to Hold Fourth Quarter Financial Results Conference Call and Webcast on Th
www.nasdaq.com - March 9 at 5:01 PM
finance.yahoo.com logoCatalyst Pharmaceuticals to Hold Fourth Quarter Financial Results Conference Call and Webcast on Thursday, March 16th, 2017
finance.yahoo.com - March 9 at 5:01 PM
finance.yahoo.com logoCatalyst Pharma (CPRX): What???s in Store in Q4 Earnings?
finance.yahoo.com - March 7 at 12:13 PM

Social

Chart

Catalyst Pharmaceuticals (CPRX) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff